[Prophylaxis and differential therapy of tumorlysis syndrome].
Krych
M
M
Medizinische Klinik und Poliklinik III-Grosshadern, Ludwig-Maximilians-Universität München, Munich. matthaeus.krych@med.uni-muenchen.de
Dreyling
M
M
Kneba
M
M
Hoelzer
D
D
Hiddemann
W
W
Hallek
M
M
D000493:Allopurinol / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D012307:Risk Factors; D015275:Tumor Lysis Syndrome / Q000191:economics / Q000209:etiology* / Q000517:prevention & control; D014503:Urate Oxidase / Q000191:economics / Q000627:therapeutic use; D014527:Uric Acid / Q000378:metabolism; D014882:Water-Electrolyte Balance
D000963:Antimetabolites; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; C469709:rasburicase; D014527:Uric Acid; D000493:Allopurinol; D014503:Urate Oxidase